Carcinoid tumors are part of a heterogeneous group of gastrointestinal and pancreatic endocrine tumors that are characterized by their capacity to produce and secrete hormones, 5-hydroxytryptamine ...

Background. A 48-year-old man presented with diarrhea, flushing, abdominal pain and weight loss of 10 kg over a 6-month period. He subsequently developed dyspnea on exertion. Diagnosis. Carcinoid ...

Crinetics Pharma's Paltusotine shows strong Phase 3 results for acromegaly. Click here to find out why CRNX stock is a Buy.

Stifel initiates coverage on CRNX, a clinical-stage pharmaceutical company focused on endocrine diseases and tumors.

Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the treatment of 1) adult and pediatric patients 12 years of ...

The carcinoid tumor market is navigating through a transformative phase buoyed by technological advancements, pressing healthcare needs, and a sharpened focus on patient-specific treatment pathways.

Neuroendocrine tumors that start in the pancreas tend to be more aggressive and have a poor prognosis.

Dublin, March 14, 2025 (GLOBE NEWSWIRE) -- The "Carcinoid Tumor Market" report has been added to ResearchAndMarkets.com's offering. The global demand for advanced carcinoid tumor treatments is ...